VERA
VENTE TOTALE: 18 500 titres (~649 642,30 $ US)
- Insiders
- Fordyce Marshall
- Total bought
- —
- Total sold
- $649,642
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-07
VERA is a pre-revenue biotech with zero commercial traction, persistent cash burn, and a near-total absence of positive catalysts, making the strong liquidity score insufficient to offset deep fundamental and…
The first sentence of the analysis written for VERA on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 13.635 | 25.668 | 7.713 | 4.910 | 10.733 | |
| Quick Ratio | 13.635 | 25.668 | 7.713 | 4.910 | 10.733 | |
| Solvency Ratio | -2.297 | -1.936 | -1.299 | -1.649 | -2.291 | |
| Cash Ratio | 6.636 | 3.652 | 2.048 | 1.698 | 10.361 | |
| Price To Earnings Ratio | -10.867 | -15.378 | -6.836 | -5.776 | -10.996 | |
| Price To Earnings Growth Ratio | -0.156 | -0.692 | 0.208 | -0.153 | 0.132 | |
| Forward Price To Earnings Growth Ratio | -0.156 | -0.692 | 0.208 | -0.153 | 0.132 | |
| Price To Earnings Diluted Ratio | -10.867 | -15.378 | -6.836 | -5.776 | -10.996 | |
| Price To Earnings Diluted Growth Ratio | -0.156 | -0.692 | 0.208 | -0.153 | 0.132 | |
| Price To Book Ratio | 5.381 | 4.054 | 6.460 | 6.685 | 5.159 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -13.456 | -17.248 | -7.121 | -7.599 | -15.143 | |
| Price To Operating Cash Flow Ratio | -13.491 | -17.373 | -7.125 | -7.606 | -15.143 | |
| Debt To Assets Ratio | 0.105 | 0.083 | 0.306 | 0.238 | 0.059 | |
| Debt To Equity Ratio | 0.128 | 0.095 | 0.528 | 0.407 | 0.071 | |
| Debt To Capital Ratio | 0.113 | 0.086 | 0.346 | 0.289 | 0.066 | |
| Long Term Debt To Capital Ratio | 0.110 | 0.081 | 0.329 | 0.244 | 0.066 | |
| Financial Leverage Ratio | 1.215 | 1.136 | 1.726 | 1.709 | 1.203 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.510 | -5.308 | -4.133 | -2.640 | -3.083 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | 1.007 | 1.001 | 1.001 | 1.000 | |
| Debt Service Coverage Ratio | -38.722 | -18.937 | -24.348 | -89.627 | -1,620.650 | |
| Interest Coverage Ratio | -41.890 | -21.921 | -26.945 | -91.636 | -1,720.100 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.119 | -2.465 | -1.716 | -2.161 | -4.816 | |
| Capital Expenditure Coverage Ratio | -382.705 | -138.559 | -1,463.190 | -1,090.258 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -382.705 | -138.559 | -1,463.190 | -1,090.258 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -10.203 | -15.938 | -7.212 | -5.646 | -8.770 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 13.636 | ▼-12.032 | ▲1.104 |
| Quick Ratio | 13.636 | ▼-12.032 | ▲1.104 |
| Solvency Ratio | -2.297 | ▼-0.361 | ▼-0.403 |
| Cash Ratio | 6.636 | ▲2.984 | ▲1.757 |
| Price To Earnings Ratio | -10.867 | ▲4.511 | ▼-0.896 |
| Price To Earnings Growth Ratio | -0.157 | ▲0.536 | ▼-0.024 |
| Forward Price To Earnings Growth Ratio | -0.157 | ▲0.536 | ▼-0.024 |
| Price To Earnings Diluted Ratio | -10.867 | ▲4.511 | ▼-0.896 |
| Price To Earnings Diluted Growth Ratio | -0.157 | ▲0.536 | ▼-0.024 |
| Price To Book Ratio | 5.381 | ▲1.327 | ▼-0.167 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -13.456 | ▲3.792 | ▼-1.343 |
| Price To Operating Cash Flow Ratio | -13.491 | ▲3.882 | ▼-1.344 |
| Debt To Assets Ratio | 0.105 | ▲0.022 | ▼-0.053 |
| Debt To Equity Ratio | 0.128 | ▲0.033 | ▼-0.118 |
| Debt To Capital Ratio | 0.113 | ▲0.027 | ▼-0.067 |
| Long Term Debt To Capital Ratio | 0.110 | ▲0.029 | ▼-0.056 |
| Financial Leverage Ratio | 1.215 | ▲0.079 | ▼-0.183 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.510 | ▲0.798 | ▼-0.575 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | ▼-0.005 | ▲0.000 |
| Debt Service Coverage Ratio | -38.722 | ▼-19.785 | ▲319.735 |
| Interest Coverage Ratio | -41.890 | ▼-19.969 | ▲338.608 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -3.119 | ▼-0.654 | ▼-0.264 |
| Capital Expenditure Coverage Ratio | -382.705 | ▼-244.146 | ▲232.238 |
| Dividend Paid And Capex Coverage Ratio | -382.705 | ▼-244.146 | ▲232.238 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -10.203 | ▲5.735 | ▼-0.649 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.25B | $2.34B | $656.8M | $514.1M | $359.0M | |
| Enterprise value | $2.98B | $2.30B | $664.9M | $502.0M | $284.3M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -12.34x | -17.09x | -7.21x | -7.43x | -11.99x | |
| EV / Free cash flow | -12.31x | -16.97x | -7.21x | -7.42x | -11.99x | |
| EV / EBITDA | -10.20x | -15.94x | -7.21x | -5.65x | -8.77x | |
| Net debt / EBITDA | 0.95x | 0.26x | -0.09x | 0.14x | 2.31x | |
| Current ratio | 13.63x | 25.67x | 7.71x | 4.91x | 10.73x | |
| Income quality | 0.81x | 0.89x | 0.96x | 0.76x | 0.73x | |
| Graham net-net | $9 | $10 | $2 | $2 | $5 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 102.6% | 105.3% | 104.1% | 101.1% | 100.1% | |
| Working capital | $675.4M | $625.8M | $149.7M | $100.1M | $74.8M | |
| Invested capital | $677.4M | $630.2M | $152.8M | $105.3M | $74.8M | |
| Return on assets | -40.8% | -23.2% | -54.7% | -67.8% | -38.9% | |
| Operating ROA | -45.4% | -40.2% | -66.5% | -84.5% | -49.7% | |
| Return on tangible assets | -40.8% | -23.2% | -54.7% | -67.8% | -38.9% | |
| Return on equity | -49.6% | -26.4% | -94.4% | -115.8% | -46.9% | |
| Return on invested capital | -46.3% | -26.5% | -65.5% | -83.8% | -45.2% | |
| Return on capital employed | -46.3% | -26.5% | -66.6% | -85.9% | -45.2% | |
| Earnings yield | -9.2% | -6.5% | -14.6% | -17.3% | -9.1% | |
| Free cash flow yield | -7.4% | -5.8% | -14.0% | -13.2% | -6.6% | |
| Capex / Op. cash flow | -0.3% | -0.7% | -0.1% | -0.1% | 0.0% | |
| Capex / Depreciation | 134.6% | 925.7% | -1.5% | -7.3% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | -5173d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 5173d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+39.0%EV / Sales n/aEV / EBITDA ▲+36.0%EV / Op. cash flow ▲+4.750Earnings yield ▼-0.027
Profitability
Return on equity ▼-0.232Return on assets ▼-0.176Return on invested capital ▼-0.198Return on capital employed ▼-0.198Operating ROA ▼-0.052Income quality ▼-0.080Tax burden -0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-12.032Net debt / EBITDA ▲+0.688Working capital ▲+49581000.000Invested capital ▲+47172000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+806.1%EV / Sales n/aEV / EBITDA ▼-16.3%EV / Op. cash flow ▼-0.351Earnings yield ▼-0.001
Profitability
Return on equity ▼-0.027Return on assets ▼-0.018Return on invested capital ▼-0.010Return on capital employed ▼-0.011Operating ROA ▲+0.044Income quality ▲+0.078Tax burden -0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+2.902Net debt / EBITDA ▼-1.355Working capital ▲+600581000.000Invested capital ▲+602504000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-04 Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
- 2026-09-01 Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company''s management team will present and participate in one-on-one meetings at upcoming investor conferences.
- 2026-08-17 Vera Therapeutics: FDA''s eGFR Analysis Supports A Speculative Buy Vera Therapeutics is upgraded to Buy following TRUTAKNA''s FDA approval and encouraging eGFR data. The FDA''s exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka''s VOYXACT and Vertex''s povetacicept but enjoys a commercial head start and broad label.
- 2026-08-12 E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA E. Ohman J or Asset Management AB grew its holdings in Vera Therapeutics, Inc. (NASDAQ: VERA) by 99.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,777 shares of the company''s stock after purchasing an additional 42,787 shares during
- 2026-08-07 Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 63,011 shares of Class A common stock and restricted stock units (RSUs) underlying 44,987 shares of Class A common stock to Nancy Bowman, M.D.
- 2026-07-11 Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression.
- 2026-07-10 Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
- 2026-07-09 Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position.
- 2026-07-07 Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
- 2026-07-07 US FDA approves Vera''s kidney disease drug The U.S. Food and Drug Administration has approved Vera Therapeutics'' drug to treat patients with a potentially life-threatening kidney disease, the regulator said on Tuesday, sending its shares up 6.2% in afternoon trading.